Page last updated: 2024-12-06

lead chromate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

lead chromate: RN given refers to unspecified lead chromate [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

lead chromate : A chromium coordination entity comprising chromate and lead(2+) ions in a 1:1 ratio [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID24460
CHEBI ID86257
MeSH IDM0099866

Synonyms (41)

Synonym
7758-97-6
lead chromate(vi)
einecs 231-846-0
hsdb 1650
chromate de plomb [french]
ccris 357
chromic acid, lead(2+) salt (1:1)
phoenicochroite
lead chromate (pbcro4)
chromic acid (h2cro4), lead(2+) salt (1:1)
plumbous chromate
lead chromate
lead chromate yellow
11119-70-3
1344-37-2
unii-aa3229aous
lead(ii) chromate
chromate de plomb
aa3229aous ,
chromium lead oxide
basic lead chromate
chromic acid, lead salt, basic
chromic acid, lead salt
lead chrome yellow
chromic acid (h2cro4), lead(2 ) salt
15804-54-3
AKOS015902900
lead chromate [hsdb]
lead chromate(vi) [mi]
lead chromate (vi)
plumbum chromicum [hpus]
plumbum chromicum
DTXSID1064792
MOUPNEIJQCETIW-UHFFFAOYSA-N
CHEBI:86257
lead(2+) dioxido(dioxo)chromium
chrome yellow 34
mfcd00011158
lead (ii) chromate
Q367871
dioxido(dioxo)chromium;lead(2+)

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" A clear dose-response relationship was observed for the induction of morphological transformation for each compound, either previously solubilized or in suspension."( Role of solubilized chromium in the induction of morphological transformation of Syrian hamster embryo (SHE) cells by particulate chromium(VI) compounds.
Baruthio, F; Danière, MC; Elias, Z; Poirot, O, 1991
)
0.28
" Soluble hexavalent CaCrO4, administered in either acute (5-h) or subacute (24-h) dosing regimens, induced dose-dependent cytotoxicity and mutation to 6-thioguanine resistance in Chinese hamster ovary cells but no mutation to ouabain resistance or focus formation in transformation assays, although the acute treatment induced a high frequency of conversion of 10T1/2 cells to adipocytes."( Transformation of C3H/10T1/2 mouse embryo cells to focus formation and anchorage independence by insoluble lead chromate but not soluble calcium chromate: relationship to mutagenesis and internalization of lead chromate particles.
Banh, D; Landolph, JR; Patierno, SR, 1988
)
0.49
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
carcinogenic agentA role played by a chemical compound which is known to induce a process of carcinogenesis by corrupting normal cellular pathways, leading to the acquistion of tumoral capabilities.
neurotoxinA poison that interferes with the functions of the nervous system.
nephrotoxinA poison that interferes with the function of the kidneys.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
lead coordination entity
chromium coordination entity
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (61)

TimeframeStudies, This Drug (%)All Drugs %
pre-199013 (21.31)18.7374
1990's12 (19.67)18.2507
2000's20 (32.79)29.6817
2010's12 (19.67)24.3611
2020's4 (6.56)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 61.91

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index61.91 (24.57)
Research Supply Index4.23 (2.92)
Research Growth Index4.58 (4.65)
Search Engine Demand Index101.07 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (61.91)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies2 (2.94%)4.05%
Observational0 (0.00%)0.25%
Other66 (97.06%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]